Valeant Pharmaceuticals International is laying off 77 employees at Seattle-based Dendreon’s operations, according to a WARN notice received by the state Employment Security Department.
An article in The Seattle Times said the layoffs began Feb. 23, immediately after completion of the $495 million sale of Dendreon’s prostate cancer drug, Provenge, and other assets.
The article went on to say that Valeant spokeswoman Laurie Little said, “most of these positions were in G&A functions where there was overlap with Valeant’s existing businesses, especially in corporate and back office functions.”
Read the full story
